

Correction to *Lancet Diabetes & Endocrinology* 2025; 13: 591–99

Amylidi-Mohr S, Zennaro G, Schneider S, Raio L, Mosimann B, Surbek D. Continuous glucose monitoring in the management of gestational diabetes in Switzerland (DipGluMo): an open-label, single-centre, randomised, controlled trial. *Lancet Diabetes Endocrinology* 2025; **13**: 591–99—In this Article, the time above range percentage for the SMGB control group in table 4 should have been 2.3%. This correction has been made to the online version as of Dec 22, 2025.

Published Online
December 22, 2025
[https://doi.org/10.1016/S2213-8587\(25\)00403-6](https://doi.org/10.1016/S2213-8587(25)00403-6)

Correction to *Lancet Diabetes & Endocrinology* 2026; 14: 105–08

Yoo SGK, Teufel F, Theilmann M, et al. GLP-1 receptor agonists for obesity: eligibility across 99 countries. *Lancet Diabetes & Endocrinology* 2026; **14**: 105–08—In this Correspondence, the corresponding author's email address should have been syoo@georgeinstitute.org.au. This correction has been made to the online version as of Jan 12, 2026.

Published Online
January 12, 2026
[https://doi.org/10.1016/S2213-8587\(25\)00426-7](https://doi.org/10.1016/S2213-8587(25)00426-7)